Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Gains from Investment Securities: 2016-2025

Historic Gains from Investment Securities for Anaptysbio (ANAB) over the last 6 years, with Sep 2025 value amounting to -$22.5 million.

  • Anaptysbio's Gains from Investment Securities fell 46.08% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.0 million, marking a year-over-year decrease of 2.23%. This contributed to the annual value of $7.5 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's Gains from Investment Securities is -$22.5 million, which was down 14.84% from -$19.6 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Gains from Investment Securities registered a high of $40.2 million during Q4 2024, and its lowest value of -$24.8 million during Q2 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$4.4 million (2023), whereas its average is -$4.8 million.
  • Data for Anaptysbio's Gains from Investment Securities shows a peak YoY increase of 273.06% (in 2024) and a maximum YoY decrease of 468.47% (in 2024) over the last 5 years.
  • Anaptysbio's Gains from Investment Securities (Quarterly) stood at $20.7 million in 2021, then crashed by 128.37% to $16.9 million in 2022, then decreased by 22.14% to $13.1 million in 2023, then surged by 206.19% to $40.2 million in 2024, then slumped by 46.08% to -$22.5 million in 2025.
  • Its Gains from Investment Securities stands at -$22.5 million for Q3 2025, versus -$19.6 million for Q2 2025 and -$18.1 million for Q1 2025.